Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 65 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Mentioned in the study description
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Mentioned in the study description
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study looks at how often ATTR, a buildup of a protein called transthyretin, occurs in people with heart failure whose hearts still pump normally (HFpEF). It is for adults age 65 or older with HFpEF. The goal is to find clues that help spot ATTR earlier so treatment can start.
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Have a confirmed diagnosis of HFpEF, heart failure in which the heart still pumps normally.
- Be age 65 or older.
Who can't join
- Have end-stage kidney disease and receive dialysis, a treatment that filters the blood.
- The rule about past heart failure with weak pumping (HFrEF) is unclear. It says “no history,” with exceptions for weak pumping during certain sudden heart problems. Ask the study team to explain.
- Had a negative 99mTc-pyrophosphate scan, a test used to check for ATTR, within the past year.
- Cannot lie down for 15 minutes for the scan.
- Already have a diagnosis of amyloidosis, a disease caused by protein buildup.
- Have moderate to severe heart valve disease that has not been corrected.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Patients with a confirmed diagnosis of HFpEF. * Age ≥65 years old Exclusion Criteria: * End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min) * no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc * Negative 99mTc-pyrophosphate scan within a year * Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan * Known diagnosis of amyloidosis * Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)
Study sites (1)
MA
- Massachusetts General Hospital · Boston, MA 02114Heather Jameson, PhD · Study contactHanna Gaggin, MD · Principal investigatorMore trials in Boston